Chronic Respiratory Disorders and Their Treatment among Older People with Intellectual Disability and/or Autism Spectrum Disorder in Comparison with the General Population

Anna Axmon 1,*, Peter Höglund 2 and Gerd Ahlström 3,*

1 Division of Occupational and Environmental Medicine, Lund University, SE-221 00 Lund, Sweden; anna.axmon@med.lu.se
2 Division of Clinical Chemistry and Pharmacology, Lund University, SE-221 00 Lund, Sweden; peter.hoglund@med.lu.se
3 Department of Health Sciences, Lund University, SE-221 00 Lund, Sweden
* Correspondence: gerd.ahlstrom@med.lu.se; Tel.: +46-46-222-1916

Received: 27 June 2017; Accepted: 27 July 2017; Published: 1 August 2017

Abstract: Respiratory disorders are common among people with intellectual disabilities (ID). However, few studies have investigated these disorders among older people with ID. We identified 7936 people, aged 55+ years, with ID and a reference cohort from the general population. Data on diagnoses of chronic respiratory disorders, with a focus on asthma and chronic obstructive pulmonary disease (COPD), were collected, as was information on health care visits due to such disorders. We also added data on the prescription of drugs for obstructive airway diseases. Whereas the risk of having at least one diagnosis of asthma during the study period was similar in the two cohorts, people with ID were less likely than the general population to have been diagnosed with COPD. The same was found for health care visits due to asthma and COPD, respectively. The patterns of drug prescription were similar among people with ID and the general population, with the exception of adrenergics for systemic use, which were more commonly prescribed to people with ID. Thus, older people with ID do not seem to have an increased risk of asthma or COPD. Moreover, the indications are that when diagnosed with any of these disorders, they receive treatment adapted to their particular needs.

Keywords: asthma; pulmonary disease; chronic obstructive; middle aged; aged; diagnosis; delivery of health care; pharmaceutical preparations

1. Introduction

Respiratory disorders are more common among people with intellectual disabilities (ID) than in the general population [1]. Also, people with ID are more likely to visit the emergency department for respiratory diseases [2], and hospital admissions are more frequent [3,4], of longer duration, and have a higher likelihood of recurring among people with ID than in the general population [3]. Compared to the general population, people with ID are more likely to die from respiratory infections [5,6]. Indeed, respiratory diseases are one of the most common causes of death among people with ID [7–12].

Asthma and chronic obstructive pulmonary disease (COPD) are two types of chronic inflammatory respiratory diseases. Several [13–18] but not all [1] studies indicate that asthma is more common among people with ID than in the general population. However, the increased risk is not as evident among people aged 55 years or more [18]. Nevertheless, asthma is more likely to cause death among people with ID than in the general population [19], and people with ID and asthma are more likely to be hospitalized than people with asthma without ID [20]. COPD in people with ID has been less
studied. However, indications are that it is less common in populations with ID than in the general population [6,17,18,21], regardless of age [18].

Both asthma [22,23] and COPD [24,25] have been found to be associated with a high comorbidity burden. Also, people with uncontrolled (i.e., untreated) asthma have a lower quality of life than those with partially or fully controlled asthma [26], and a higher severity of COPD has been found to be associated with lower health-related quality of life (HRQoL), measured by the generic EuroQoL-5D (EQ-5D) [27] and the disease specific instrument COPD assessment test (CAT) [28]. However, comorbidities and demographics (sex and age) as well as socioeconomic factors influenced the HRQoL [27,28]. Therefore, it is of importance that these people receive comprehensive medical examinations and are treated properly according to their individual needs. Among people with ID, who are already disadvantaged when it comes to comorbidity [1,29] and quality of life [30], it is even more important.

Asthma and COPD are commonly treated using two drug components; a long-term control medication to reduce the number of attacks and rescue medications for symptom relief during attacks. Both long-term and rescue medication may be provided either as an inhaler or for oral intake. Studies regarding asthma treatment among people with ID have found that 86% are prescribed inhaled medications [31]. However, due to their cognitive impairment, they are likely to require support with the use of an inhaler [32]. This is especially important considering recent findings about health behavior risk factors for death due to asthma in a community based case-control study. People in the general population with poor inhaler technique were found to have a somewhat increased risk of asthma death [19].

Allergies and asthma affect individuals in all age groups but are often unrecognized or undertreated in the elderly [33]. Even so, aging increases the prevalence of asthma [22] and COPD [34] in the general population. Also among people with ID, the frequency of respiratory conditions has been found to increase with age [35], yet only a limited number of studies have focused on the prevalence and treatment of asthma and/or COPD among older people with ID.

The aim of the present study was to describe diagnoses and treatment of asthma and COPD among older people with ID in relation to their age peers in the general population and, furthermore, to relate diagnoses to treatment in these two populations.

2. Materials and Methods

This study is register based, using Swedish national registers both to establish the study cohorts and to identify outcomes (diagnoses and drug prescriptions). The two study cohorts have been described in detail elsewhere [1,29,36,37]. Briefly, all people aged 55+ years and alive at the end of 2012, and having received at least one measure of service or support provided for people with ID and/or autism spectrum disorder (ASD) during 2012, comprised the ID cohort (n = 7936, 3609 women and 4327 men). As we were not able to separate those with ID with or without ASD from those with ASD only, we used having received support as a proxy for ID. A referent cohort (gPop cohort) was randomly selected from the general population using a one-to-one match by sex and year of birth.

Data on diagnoses made in inpatient and outpatient specialist care during the study period (2006–2012) were collected from the Swedish National Patient Register. Both primary and secondary diagnoses were used to determine if a person had a diagnosis of a chronic respiratory disease. Although the main focus was on asthma (J45 in the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)) and other chronic obstructive pulmonary diseases (COPD; J44), we also present data on diagnoses of other chronic respiratory diseases, i.e., bronchitis, not specified as acute or chronic (J40), simple and mucopurulent chronic bronchitis (J41), unspecified chronic bronchitis (J42), emphysema (J43), status asthmaticus (J46), and bronchiectasis (J47).

Treatment for respiratory disorders was assessed using the prescription of drugs as well as health care utilization estimated by inpatient and outpatient specialist care due to (i.e., with primary diagnosis) any of the disorders listed above. The Swedish National Register of Prescribed Drugs was
used to collect information on dispensed drugs for obstructive airway diseases (R03 in the Anatomical Therapeutic Chemical (ATC) classification system), which were analyzed separately for adrenergics and inhalants (R03A), glucocorticoids (R03BA), anticholinergics (R03BB), adrenergics for systemic use (R03C), and other systemic drugs (R03D).

Relative risks (RRs) with 95% confidence intervals (CIs) were estimated using Generalized Linear Models (GENLIN) in IBM SPSS Statistics 23.0. The results are only presented for groups with five or more observations. P-values below 0.05 are considered statistically significant.

Approval for the study was obtained from the Regional Ethical Review Board in Lund (no. 2013/15). The National Board of Health and Welfare performed a separate secrecy review in 2014 before providing access to the data. All analyses were performed using anonymized datasets.

3. Results

3.1. Health Care Utilization

People with ID were less likely than those in the gPop cohort to have had at least one inpatient or outpatient specialist visit due to chronic respiratory diseases (Table 1). The results were similar for men and women. There were no differences between men and women in either cohort. The pattern was the same for visits due to COPD. There was no statistically significant difference between the two cohorts with respect to health care utilization for asthma, although, when stratifying on sex, the men in the ID cohort had borderline significantly lower health care utilization than the men in the gPop cohort. Also, within the ID cohort, men were less likely than women to have had an inpatient or outpatient specialist visit due to asthma. This effect of sex was not found in the gPop cohort.
Table 1. The number of people with at least one inpatient or outpatient specialist visit due to different types of chronic respiratory diseases in a cohort of people with intellectual disabilities (ID, n = 7936) and a same-sized referent sample from the general population (gPop), matched by sex and year of birth.

| Primary Diagnosis at Visit | gPop | ID |
|----------------------------|------|----|
|                            | Women | Men | Women vs. Men | Women | Men | Women vs. Men |
|                            | n (%) | n (%) | RR* (95% CI) | n (%) | n (%) | RR* (95% CI) |
| Any                        | 252 (3) | 119 (3) | 133 (3) | 0.93 (0.73–1.19) | 152 (2) | 77 (2) | 0.60 (0.49–0.74) | 75 (2) | 0.56 (0.43–0.75) | 0.81 (0.59–1.11) |
| Bronchitis, not specified as acute or chronic | 15 (0) | 7 (0) | 8 (0) | 0.95 (0.35–2.63) | 14 (0) | 6 (0) | 0.93 (0.45–1.93) | 6 (0) | 0.86 (0.29–2.55) | 8 (0) | 1.00 (0.36–2.66) | 1.11 (0.39–3.20) |
| Simple and mucopurulent chronic bronchitis | 13 (0) | 5 (0) | 8 (0) | 1.34 (0.44–4.08) | <5 | <5 | <5 | <5 | <5 | <5 | <5 |
| Unspecified chronic bronchitis | 10 (0) | 8 (0) | <5 | 6 (0) | 0.60 (0.22–1.65) | 5 (0) | 0.63 (0.21–1.91) | <5 | <5 | <5 |
| Emphysema                   | 10 (0) | <5 | 6 (0) | <5 | <5 | <5 |
| Other chronic obstructive pulmonary disease (COPD) | 137 (2) | 60 (2) | 77 (2) | 1.07 (0.77–1.50) | 64 (1) | 26 (1) | 0.43 (0.27–0.69) | 38 (1) | 0.49 (0.34–0.73) | 1.22 (0.74–2.00) |
| Asthma                      | 105 (1) | 51 (1) | 54 (1) | 0.88 (0.60–1.29) | 85 (1) | 49 (1) | 0.96 (0.65–1.42) | 36 (1) | 0.67 (0.44–1.01) | 0.61 (0.40–0.94) |
| Status asthmaticus          | 10 (0) | <5 | 6 (0) | <5 | <5 | <5 |
| Bronchiectasis              | 9 (0) | 6 (0) | <5 | <5 | <5 |

*: ID vs. gPop; b: Within the ID cohort. Note: Relative risks (RRs) are given with 95% confidence intervals (CIs). RRs are presented only if both groups to be compared are comprised of at least five individuals.
3.2. Drug Prescriptions

People in the ID cohort were less likely than people in the gPop cohort to be prescribed at least one drug for an obstructive airway disease (ATC-code R03; 12% vs. 19%; RR 0.64 [0.59–0.69]). The same pattern was found in separate analyses of men (10% vs. 16%; RR 0.64 [0.58–0.72]) and women (14% vs. 22%; RR 0.63 [0.57–0.70]). Within both the ID (RR 0.74 [0.65–0.83]) and the gPop cohort (RR 0.72 [0.66–0.79]), men were less likely than women to be prescribed at least one drug for an obstructive airway disease. All drugs for obstructive airway diseases that were prescribed and dispensed during the study period are described in Table 2.

| Drug | gPop | ID |
|------|------|----|
|      | Total | Women | Men | Total | Women | Men |
| R03AC02: salbutamol | 299 | 180 | 119 | 255 | 143 | 112 |
| R03AC03: terbutaline | 758 | 421 | 337 | 379 | 218 | 161 |
| R03AC12: salmeterol | 43 | 21 | 22 | 13 | 9 | 4 |
| R03AC13: formoterol | 186 | 102 | 84 | 74 | 40 | 34 |
| R03AC18: indacaterol | 13 | 6 | 7 | 1 | 0 | 1 |
| R03AK06: salmeterol and fluticasone | 141 | 79 | 62 | 86 | 52 | 34 |
| R03AK07: formoterol and budesonide | 472 | 235 | 237 | 203 | 108 | 95 |
| R03AK08: formoterol and beclometasone | 5 | 3 | 2 | 15 | 9 | 6 |
| R03AL02: salbutamol and ipratropium bromide | 32 | 14 | 18 | 77 | 35 | 42 |
| R03BA01: beclometasone | 23 | 12 | 11 | 21 | 6 | 15 |
| R03BA02: budesonide | 633 | 353 | 280 | 314 | 179 | 135 |
| R03BA05: fluticasone | 43 | 23 | 20 | 69 | 39 | 30 |
| R03BA07: mometasone | 26 | 14 | 12 | 6 | 4 | 2 |
| R03BA08: ciclesonide | 1 | 0 | 1 | 0 | 0 | 0 |
| R03BB01: ipratropium bromide | 103 | 56 | 47 | 73 | 30 | 43 |
| R03BB04: tiotropium bromide | 260 | 137 | 123 | 109 | 52 | 57 |
| R03BC01: cromoglicic acid | 11 | 8 | 3 | 0 | 0 | 0 |
| R03CA02: ephedrine | 2 | 1 | 1 | 0 | 0 | 0 |
| R03CC02: salbutamol | 9 | 6 | 3 | 76 | 44 | 32 |
| R03CC03: terbutaline | 14 | 7 | 7 | 176 | 93 | 83 |
| R03CC12: bamberterol | 2 | 1 | 1 | 49 | 28 | 21 |
| R03DA02: choline theophyllinate | 2 | 0 | 2 | 52 | 26 | 26 |
| R03DA04: theophylline | 5 | 3 | 2 | 28 | 12 | 16 |
| R03DC03: montelukast | 86 | 44 | 42 | 61 | 32 | 29 |
| R03DX07: roflumilast | 5 | 0 | 5 | 2 | 1 | 1 |

3.3. Diagnoses

People in the ID cohort were less likely than those in the gPop cohort to have at least one diagnosis (including both primary and secondary diagnoses) of chronic respiratory disease during the study period (Table 3). The effect was slightly larger among men than among women. Within the ID but not the gPop cohort, men were less likely than women to have at least one diagnosis of chronic respiratory disease during the study period.
Table 3. The number of people with at least one diagnosis (primary or secondary) of different types of chronic respiratory diseases in a cohort of people with intellectual disabilities (ID, \( n = 7936 \), 3609 women and 4327 men) and a same-sized referent sample from the general population (gPop), matched by sex and year of birth.

| Diagnosis                                             | gPop        | ID          |
|-------------------------------------------------------|-------------|-------------|
|                                                       | All (\( n \)) | Women (\( \% \)) | Men (\( \% \)) | Women vs. Men RR (95% CI) | n (\( \% \)) | RR (95% CI) |
|                                                       |             |             |             |                           |              |             |
| Any                                                   | 434 (5)     | 205 (6)     | 229 (5)     | 0.93 (0.76–1.12)          | 302 (4)      | 0.70 (0.60–0.80) |
| Bronchitis, not specified as acute or chronic         | 19 (0)      | 7 (0)       | 12 (0)      | 1.43 (0.56–3.63)          | 21 (0)       | 1.11 (0.60–2.05) |
| Simple and mucopurulent chronic bronchitis            | 21 (0)      | 7 (0)       | 14 (0)      | 1.69 (0.67–4.13)          | <5           | <5           |
| Unspecified chronic bronchitis                        | 21 (0)      | 13 (0)      | 8 (0)       | 0.31 (0.21–1.24)          | 11 (0)       | 0.34 (0.25–1.39) |
| Emphysema                                             | 19 (0)      | 7 (0)       | 12 (0)      | 1.43 (0.56–3.63)          | 5 (0)        | 0.26 (0.10–0.70) |
| Other chronic obstructive pulmonary disease (COPD)    | 233 (3)     | 104 (3)     | 129 (3)     | 1.04 (0.80–1.33)          | 125 (2)      | 0.54 (0.43–0.67) |
| Asthma                                                | 219 (3)     | 114 (3)     | 105 (2)     | 0.77 (0.59–1.00)          | 187 (2)      | 0.85 (0.70–1.04) |
| Status asthmaticus                                    | 12 (0)      | <5          | 8 (0)       | 0.70 (0.39–1.33)          | <5           | <5           |
| Bronchiectasis                                        | 12 (0)      | 8 (0)       | <5          | <5                        | <5           | <5           |

\( a \): ID vs. gPop. 
\( b \): Within the cohort. Note: Relative risks (RRs) are given with 95% confidence intervals (CIs). RRs are presented only if both groups to be compared are comprised of at least five individuals.
The most common diagnoses in both the ID and the gPop cohort were asthma and COPD (Table 3). Among those with at least one diagnosis of asthma or COPD, COPD was the most common diagnosis in the ID cohort and asthma in the gPop cohort (Table 3).

Whereas the risk of diagnosis of asthma was similar in the two cohorts, diagnoses of COPD were less common in the ID cohort than in the gPop cohort (Table 3). The patterns were similar in separate analyses for women and men. Men were less likely to be diagnosed with asthma in both cohorts. There were, however, no sex differences with respect to the diagnosis of COPD in either cohort.

3.4. Diagnoses vs. Drug Prescriptions

In the ID cohort, 698 people had at least one prescription of drugs for an obstructive airway disease but no diagnosis of asthma or COPD during the study period (Table 4). A further 26 had at least one diagnosis of asthma and/or COPD but no prescription of drugs for an obstructive airway disease. In the gPop cohort, 1122 people had a prescription but no diagnosis, and 28 had a diagnosis but no prescription.
Table 4. Prescription of drugs for obstructive airway diseases stratified by diagnoses of asthma and chronic obstructive airway disease in a cohort of people with intellectual disabilities (ID) and a referent sample from the general population (gPop).

| Drugs           | gPop                      | ID                      |
|-----------------|---------------------------|-------------------------|
|                 | No Diagnosis (n = 7538)   | Asthma Only (n = 17945\%a) | COPD Only (n = 16541\%a) | Asthma and COPD (n = 5414\%a) |
|                 | n (%)                     | n (%)                   | n (%)                   | n (%)                   |
| At least one R03 | 1122 (15)                 | 156 (87)                | 160 (97)                | 54 (100)                |
| R03A: Adrenergics, inhalants | 932 (12)             | 135 (75)                | 137 (95)                | 54 (100)                |
| R03BA: Glucocorticoids | 495 (7)               | 57 (32)                 | 110 (67)                | 34 (63)                 |
| R03BB: Anticholinergics | 141 (2)               | 112 (63)                | 20 (12)                 | 39 (72)                 |
| R03C: Adrenergics for systemic use | 21 (0)               | 1 (1)                   | 5 (3)                   | 0 (0)                   |
| R03D: Other systemic drugs | 45 (1)               | 11 (6)                  | 26 (16)                 | 13 (24)                 |
|                 | gPop                      | ID                      |
|                 | No Diagnosis (n = 7660)   | Asthma Only (n = 8932\%a) | COPD Only (n = 15155\%a) | Asthma and COPD (n = 3613\%a) |
|                 | n (%)                     | n (%)                   | n (%)                   | n (%)                   |
| At least one R03 | 698 (9)                   | 73 (82)                 | 142 (94)                | 35 (97)                 |
| R03A: Adrenergics, inhalants | 490 (6)               | 65 (73)                 | 129 (85)                | 33 (92)                 |
| R03BA: Glucocorticoids | 208 (3)               | 25 (28)                 | 88 (58)                 | 22 (61)                 |
| R03BB: Anticholinergics | 73 (1)               | 52 (58)                 | 18 (12)                 | 16 (44)                 |
| R03C: Adrenergics for systemic use | 194 (3)             | 11 (12)                 | 52 (34)                 | 12 (33)                 |
| R03D: Other systemic drugs | 69 (1)               | 10 (11)                 | 38 (25)                 | 5 (14)                  |

\(^{a}\): Percentage based on the number of people with at least one diagnosis.
Among those with a diagnosis of COPD during the study period, people in the ID cohort were more likely than those in the gPop cohort to be prescribed adrenergics for systemic use (Figure 1).

The results were similar when stratified by sex, although the number of men with prescriptions of adrenergics for systemic use was too low to investigate (Table 5). Among those with a diagnosis of asthma, people in the ID cohort were less likely than those in the gPop cohort to be prescribed adrenergics, inhalants, and anticholinergics but more likely to be prescribed adrenergics for systemic use (Table 5). No differences were found for the other drug types. When stratifying by sex, the differences were primarily found among the women (Table 5).

Table 5. Relative risks (RRs) with 95% confidence intervals (CIs) for ID versus gPop stratified by sex and diagnoses of COPD and asthma.

| Drug                                      | Men         | Women        |
|-------------------------------------------|-------------|--------------|
| At least one R03                          | 0.97 (0.85–1.11) | 0.95 (0.88–1.04) |
| R03A: Adrenergics, inhalants              | 1.03 (0.87–1.21) | 0.91 (0.78–1.05) |
| R03BA: Glucocorticoids                    | 1.09 (0.75–1.58) | 0.83 (0.54–1.26) |
| R03BB: Anticholinergics                   | 0.81 (0.62–1.05) | 0.88 (0.69–1.14) |
| R03C: Adrenergics for systemic use a      | 21.58 (2.86–163) |               |
| R03D: Other systemic drugs                | 0.80 (0.36–1.74) | 2.29 (0.81–6.47) |
| COPD                                      |             |              |
| At least one R03                          | 0.99 (0.93–1.05) | 0.95 (0.90–1.00) |
| R03A: Adrenergics, inhalants              | 0.92 (0.83–1.01) | 0.88 (0.82–0.95) |
| R03BA: Glucocorticoids                    | 0.88 (0.71–1.10) | 0.91 (0.73–1.12) |
| R03BB: Anticholinergics                   | 1.06 (0.62–1.81) | 0.45 (0.26–0.78) |
| R03C: Adrenergics for systemic use        | 9.28 (3.40–25.4) | 38.0 (5.30–272) |
| R03D: Other systemic drugs                | 1.21 (0.68–2.16) | 1.36 (0.80–2.29) |
| Asthma                                    |             |              |
| At least one R03                          | 0.99 (0.93–1.05) | 0.95 (0.90–1.00) |
| R03A: Adrenergics, inhalants              | 0.92 (0.83–1.01) | 0.88 (0.82–0.95) |
| R03BA: Glucocorticoids                    | 0.88 (0.71–1.10) | 0.91 (0.73–1.12) |
| R03BB: Anticholinergics                   | 1.06 (0.62–1.81) | 0.45 (0.26–0.78) |
| R03C: Adrenergics for systemic use        | 9.28 (3.40–25.4) | 38.0 (5.30–272) |
| R03D: Other systemic drugs                | 1.21 (0.68–2.16) | 1.36 (0.80–2.29) |

a: Not assessed for men due to low numbers of prescriptions.
4. Discussion

Whereas the risk of having been diagnosed with asthma was the same for people with ID as for the general population, diagnosis of COPD was less common among people with ID. Among those with asthma or COPD, people with ID were more likely than those in the general population to be prescribed adrenergics for systemic use.

We used the National Patient Register to collect information on respiratory disorders. A strength of this is that the register has more or less complete coverage of inpatient and outpatient specialist care in Sweden. A limitation is that it does not include visits to primary care. As both asthma and COPD are commonly treated in primary care, we are likely to have failed to include all cases of these diseases. This is reflected in the high number of people without diagnoses but with prescriptions of at least one drug for obstructive airway diseases. People who seek inpatient or outpatient specialist care for their asthma/COPD may be suspected to be more severe cases than those who do not. Thus, people with severe asthma/COPD are likely to be overrepresented in both the ID and gPop cohort, whereas those with mild asthma/COPD may be underrepresented or even absent. The numbers in the present study should therefore not be used to estimate prevalence but only for comparisons between people with ID and the general population. This is also supported by the lower percentage of people with asthma found in the gPop cohort than in other studies on middle-aged and older people [38–40]. Another potential problem with using data from secondary care only is that differences in access to such care would appear as differences in disease prevalence. This is further discussed below.

So far, studies presenting results on the risk of asthma among people with ID are somewhat contradictory, with some finding an increased risk [13,15–18] and others not [41–43]. Possible explanations for this may include differences in age groups, geographical area, and the time period studied. Moreover, the type of data used varies, with some using primary care data [15–18,43] and others using different types of survey data [13,41,42]. The most obvious explanation for the lack of a difference between the ID cohort and the gPop cohort regarding asthma diagnoses is that the two cohorts do not differ in asthma prevalence, which is supported by a previous study presenting a decreased difference in the prevalence of asthma between people with ID and the general population in age groups older than 55 years [18]. This could be the effect of a survival mechanism, i.e., that people with ID and asthma tend to die at an earlier age. The lack of difference between the two cohorts could also arise from differences in health care utilization. For example, if people with ID have an increased risk of asthma but tend to visit primary rather than secondary care and the opposite is true for the general population, the data from inpatient and outpatient specialist care would indicate similarities in asthma prevalence. However, as diagnosing asthma may be difficult in people with ID, it may be argued that people with ID and asthmatic symptoms are more likely to visit and be diagnosed in specialist care than in primary care.

The decreased risk of COPD among people with ID found in the present study is in line with previous research [6,16–18,21], despite the differences in age groups studied. Tobacco smoke is the most important cause of COPD [44], and people with ID are less likely to smoke than the general population [45–47]. Thus, differences in smoking habits between people with ID and the general population is a plausible link between ID and a decreased risk of COPD. The selection of healthier people with ID into the older age groups, as discussed for asthma above, is not evident for COPD.

Asthma is classified as an ambulatory care sensitive (ACS) condition [48]. It has been suggested that rates of hospitalization for ACS conditions may be used as a measure of access to and the quality of primary care [49]. Based on this, it has been suggested that primary health care for asthma for people with ID is suboptimal compared with the general population [50]. In the present study, we investigated asthma-related inpatient and outpatient specialist visits rather than hospitalization. Doing this, we found no differences between people with ID and the general population, with the possible exception of a smaller number with visits among men with ID. Thus, the Swedish health care system seems to be able to properly care for older people with ID and asthma.
Among those with asthma and/or COPD, people with ID were more likely than the general population to be prescribed adrenergics for systemic use. We believe that the main explanation for this is that these are easier to administer than drugs provided in inhalers, especially when it comes to people with more severe ID.

5. Conclusions

Both asthma and COPD are chronic conditions that may have a large impact on a person’s quality of life, everyday living, and long term health, especially when insufficiently treated. Among older people in general and older people with ID in particular, it is important to ensure not only that treatment is provided in proper amounts, but also that it is administered in a way that is suitable for a patient with limited abilities. Indications are that care provided to asthma/COPD patients with ID indeed is adapted to the particular needs of these patients.

Acknowledgments: This work was funded by Forte, the Swedish Research Council for Health, Working Life, and Welfare no. 2014-4753 and the Ragnhild och Einar Lundström’s Memorial Foundation.

Author Contributions: G.A. designed the original project and obtained funding and data. All authors (A.A., P.H. and G.A.) participated in the design of the present study. A.A. performed the statistical analyses and wrote the first draft of the manuscript. All authors (A.A., P.H. and G.A.) contributed to the interpretation of data and read and approved the final version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Sandberg, M.; Ahlström, G.; Kristensson, J. Patterns of somatic diagnoses in older people with intellectual disability: A Swedish eleven year case-control study of inpatient data. J. Appl. Res. Intellect. Disabil. 2015, 30, 157–171. [CrossRef] [PubMed]
2. Venkat, A.; Pastin, R.B.; Hegde, G.G.; Shea, J.M.; Cook, J.T.; Culig, C. An analysis of ED utilization by adults with intellectual disability. Am. J. Emerg. Med. 2011, 29, 401–411. [CrossRef] [PubMed]
3. Chang, C.K.; Chen, C.Y.; Broadbent, M.; Stewart, R.; O’Hara, J. Hospital admissions for respiratory system diseases in adults with intellectual disabilities in southeast London: A register-based cohort study. BMJ Open 2017, 7, e014846. [CrossRef] [PubMed]
4. Skorpen, S.; Nicolaisen, M.; Langballe, E.M. Hospitalisation in adults with intellectual disabilities compared with the general population in Norway. J. Intellect. Disabil. Res. 2016, 60, 365–377. [CrossRef] [PubMed]
5. Raitasuo, J.; Molsa, P.; Raitasuo, S.; Mattila, K. Deaths among the intellectually disabled: A retrospective study. J. Appl. Res. Intellect. Disabil. 1997, 10, 280–288. [CrossRef]
6. Tyler, C.V.; Schramm, S.; Karafa, M.; Tang, A.S.; Jain, A. Electronic health record analysis of the primary care of adults with intellectual and other developmental disabilities. J. Policy Pract. Intellect. Disabil. 2010, 7, 204–210. [CrossRef] [PubMed]
7. Glover, G.; Williams, R.; Heslop, P.; Oyinlola, J.; Grey, J. Mortality in people with intellectual disabilities in England. J. Intellect. Disabil. Res. 2017, 61, 62–74. [CrossRef] [PubMed]
8. Glasson, E.J.; Sullivan, S.G.; Hussain, R.; Bittles, A.H. An assessment of intellectual disability among aboriginal Australians. J. Intellect. Disabil. Res. 2005, 49, 626–634. [CrossRef] [PubMed]
9. Durvasula, S.; Beange, H.; Baker, W. Mortality of people with intellectual disability in northern Sydney. J. Intellect. Dev. Disabil. 2002, 27, 255–264. [CrossRef]
10. Walsh, P.N. Ageing and mental retardation. Curr. Opin. Psychiatry 2002, 15, 509–514. [CrossRef]
11. Patja, K.; Molsa, P.; Iivanainen, M. Cause-specific mortality of people with intellectual disability in a population-based, 35-year follow-up study. J. Intellect. Disabil. Res. 2001, 45, 30–40. [CrossRef] [PubMed]
12. Trollor, J.; Srasuebkul, P.; Xu, H.; Howlett, S. Cause of death and potentially avoidable deaths in Australian adults with intellectual disability using retrospective linked data. BMJ Open 2017, 7, e013489. [CrossRef] [PubMed]
Mitra, M.; Clements, K.M.; Zhang, J.Y.; Smith, L.D. Disparities in adverse preconception risk factors between women with and without disabilities. *Matern. Child Health J.* 2016, 20, 507–515. [CrossRef] [PubMed]

McCarthy, J.; O’Hara, J. Ill-health and intellectual disabilities. *Curr. Opin. Psychiatry* 2011, 24, 382–386. [CrossRef] [PubMed]

Gale, L.; Naqvi, H.; Russ, L. Asthma, smoking and bmi in adults with intellectual disabilities: A community-based survey. *J. Intellect. Disabil. Res.* 2009, 53, 787–796. [CrossRef] [PubMed]

Carey, I.M.; Shah, S.M.; Hosking, F.J.; DeWilde, S.; Harris, T.; Brightton, C.; Cook, D.G. Health characteristics and consultation patterns of people with intellectual disability: A cross-sectional database study in English general practice. *Br. J. Gen. Pract.* 2016, 66, 264–270. [CrossRef] [PubMed]

Cooper, S.A.; McLean, G.; Guthrie, B.; McConnachie, A.; Mercer, S.; Sullivan, F.; Morrison, J. Multiple physical and mental health comorbidities in adults with intellectual disabilities: Population-based cross-sectional analysis. *BMC Fam. Pract.* 2015, 16, 110. [CrossRef] [PubMed]

Sturdy, P.M.; Victor, C.R.; Anderson, H.R.; Bland, J.M.; Butland, B.K.; Harrison, B.D.; Peckitt, C.; Taylor, J.C. Psychological, social and health behaviour risk factors for deaths certified as asthma: A national case-control study. *Thorax* 2002, 57, 1034–1039. [CrossRef] [PubMed]

Balogh, R.; Brownell, M.; Ouellette-Kuntz, H.; Colantonio, A. Hospitalisation rates for ambulatory care sensitive conditions for persons with and without an intellectual disability-A population perspective. *J. Intellect. Disabil. Res.* 2010, 54, 820–832. [CrossRef] [PubMed]

Silitci, T.; Demirgan, S.; Akcay, C.; Kahraman, N.; Koseoglu, B.G.; Erdem, M.A.; Cankaya, A.B. Comparison of patients with and without intellectual disability under general anesthesia: A retrospective study. *Niger. J. Clin. Pract.* 2017, 20, 438–444. [CrossRef] [PubMed]

Kauppi, P.; Linna, M.; Jantunen, J.; Martikainen, J.E.; Hahtela, T.; Pelkonen, A.; Makela, M. Chronic comorbidities contribute to the burden and costs of persistent asthma. *Mediators Inflamm.* 2015, 2015, 819194. [CrossRef] [PubMed]

Zhang, T.; Carleton, B.C.; Prosser, R.J.; Smith, A.M. The added burden of comorbidity in patients with asthma. *J. Asthma* 2009, 46, 1021–1026. [CrossRef] [PubMed]

Mahboub, B.; Alzaabi, A.; Iqbal, M.N.; Salhi, H.; Lahlou, A.; Tariq, L.; El Hasnaoui, A. Comorbidities associated with COPD in the middle east and north Africa region: Association with severity and exacerbations. *Int. J. Chron. Obstruct. Pulmon. Dis.* 2016, 11, 273–280. [PubMed]

Lopez Varela, M.V.; Montes de Oca, M.; Halbert, R.; Muino, A.; Talamo, C.; Perez-Padilla, R.; Jardim, J.R.; Valdivia, G.; Pertuze, J.; Menezes, A.M. Comorbidities and health status in individuals with and without COPD in five Latin American cities: The platino study. *Arch. Bronconeumol.* 2013, 49, 468–474. [CrossRef] [PubMed]

Chen, W.; Lynd, L.D.; FitzGerald, J.M.; Marra, C.A.; Rousseau, R.; Sadatsafavi, M. The added effect of comorbidity on health-related quality of life in patients with asthma. *Qual. Life Res.* 2015, 24, 2507–2517. [CrossRef] [PubMed]

Axmon, A.; Björne, P.; Nylander, L.; Ahlström, G. Psychiatric diagnoses in older people with intellectual disability in comparison with the general population: A register study. *Epidemiol. Psychiatr. Sci.* 2017, 1–13. [CrossRef] [PubMed]

Sheppard-Jones, K.; Thompson Prout, H.; Kleinert, H. Quality of life dimensions for adults with developmental disabilities: A comparative study. *Ment. Retard.* 2005, 43, 281–291. [CrossRef] [PubMed]

Davis, S.R.; Durvasula, S.; Merhi, D.; Young, P.M.; Traini, D.; Bosnic-Anticevich, S.Z. Respiratory medication use in an Australian developmental disability clinic population: Messages for health care professionals. *Aust. J. Prim. Health* 2014, 20, 278–284. [CrossRef] [PubMed]
32. Davis, S. Asthma in intellectual disability: Are we managing our patients appropriately? *Breathe* 2016, 12, 310–317. [CrossRef] [PubMed]
33. Mathur, S.K. Allergy and asthma in the elderly. *Semin. Respir. Crit. Care Med.* 2010, 31, 587–595. [CrossRef] [PubMed]
34. Raherison, C.; Girodet, P.O. Epidemiology of COPD. *Eur. Respir. Rev.* 2009, 18, 213–221. [CrossRef] [PubMed]
35. Janicki, M.P.; Davidson, P.W.; Henderson, C.M.; McCallion, P.; Taets, J.D.; Force, L.T.; Sulkes, S.B.; Frangenberg, E.; Ladrigan, P.M. Health characteristics and health services utilization in older adults with intellectual disability living in community residences. *J. Intellect. Disabil. Res.* 2002, 46, 287–298. [CrossRef] [PubMed]
36. Axmon, A.; Björne, P.; Nylander, L.; Åhlström, G. Psychiatric care utilization among older people with intellectual disability in comparison with the general population: A register study. *BMC Psychiatry* 2016, 16, 389. [CrossRef] [PubMed]
37. Sandberg, M.; Åhlström, G.; Axmon, A.; Kristensson, J. Somatic healthcare utilisation patterns among older people with intellectual disability: An 11-year register study. *BMC Health Serv. Res.* 2016, 16, 642. [CrossRef] [PubMed]
38. Akinbami, L.J.; Fryar, C.D. Current asthma prevalence by weight status among adults: United States, 2001–2014. *NCHS Data Brief.* 2016, 239, 1–8.
39. Ryan-Ibarra, S.; Milet, M.; Lutzker, L.; Rodriguez, D.; Induni, M.; Kreutzer, R. Age, period, and cohort effects in adult lifetime asthma prevalence in California: An application of hierarchical age-period-cohort analysis. *Ann. Epidemiol.* 2016, 26, 87–92. [CrossRef] [PubMed]
40. Gonzalez-Garcia, M.; Caballero, A.; Jaramillo, C.; Maldonado, D.; Torres-Duque, C.A. Prevalence, risk factors and underdiagnosis of asthma and wheezing in adults 40 years and older: A population-based study. *J. Asthma* 2015, 52, 823–830. [CrossRef] [PubMed]
41. Morin, D.; Mérineau-Côté, J.; Ouellette-Kuntz, H.; Tassé, M.; Kerr, M. A comparison of the prevalence of chronic disease among people with and without intellectual disability. *Am. J. Intellect. Dev. Disabil.* 2012, 117, 455–463. [CrossRef] [PubMed]
42. Cocks, E.; Thomson, A.; Thoresen, S.; Parsons, R.; Rosenwax, L. Health status and use of medications by adults with intellectual disability in western Australia. *J. Intellect. Dev. Disabil.* 2016, 41, 87–96. [CrossRef]
43. McDermott, S.; Moran, R.; Platt, T.; Dasari, S. Variation in health conditions among groups of adults with disabilities in primary care. *J. Community Health* 2006, 31, 147–159. [CrossRef] [PubMed]
44. Mannino, D.M.; Buist, A.S. Global burden of COPD: Risk factors, prevalence, and future trends. *Lancet* 2007, 370, 765–773. [CrossRef]
45. McCarron, M.; Cleary, E.; McCallion, P. Health and health-care utilization of the older population of Ireland: Comparing the intellectual disability population and the general population. *Res. Aging* 2017, 39, 693–718. [CrossRef] [PubMed]
46. Haider, S.I.; Ansari, Z.; Vaughan, L.; Matters, H.; Emerson, E. Health and wellbeing of Victorian adults with intellectual disability compared to the general Victorian population. *Res. Dev. Disabil.* 2013, 34, 4034–4042. [CrossRef] [PubMed]
47. McGuire, B.E.; Daly, P.; Smyth, F. Lifestyle and health behaviours of adults with an intellectual disability. *J. Intell. Disabil. Res.* 2007, 51, 497–510. [CrossRef] [PubMed]
48. Purdy, S.; Griffin, T.; Salisbury, C.; Sharp, D. Ambulatory care sensitive conditions: Terminology and disease coding need to be more specific to aid policy makers and clinicians. *Public Health* 2009, 123, 169–173. [CrossRef] [PubMed]
49. Porter, J.; Herring, J.; Lacroix, J.; Levinton, C. Avoidable admissions and repeat admissions: What do they tell us? *Healthc. Q.* 2007, 10, 26–28. [CrossRef] [PubMed]
50. Dunn, K.; Hughes-McCormack, L.; Cooper, S.A. Hospital admissions for physical health conditions for people with intellectual disabilities: Systematic review. *J. Appl. Res. Intellect. Disabil.* 2017. [CrossRef] [PubMed]